Novavax

Novavax initiates preclinical testing of intranasal influenza vaccine

Published in Health Business Week, October 20th, 2006

Novavax, Inc. (NVAX) has begun preclinical testing of intranasal versions of its influenza vaccines in development, providing a potential alternative to administering these vaccines by injection.

"This is an important advancement for our existing technology because it will allow us to reach an even broader population," said Dr. Rick Bright, Novavax's vice president of Vaccine Development. "There are many parts of the world that do not have accessibility to enough sterile needles to respond to an influenza crisis."

Historically influenza vaccines have been administered though intramuscular injection. However, the World Health Organization (WHO) has...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2006-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry